Recent Updates
Recently added Catalysts
REVB Positive Sentiment

REMINDER: Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference

Tuesday, March 24, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Revelation Biosciences, Inc. will participate in a fireside chat at the 38th Annual Roth Conference on March 24, 2026. The event will take place at 2:00 p.m. PT in Dana Point, CA, and will be webcast live. The company focuses on rebalancing inflammation with its proprietary formulation, Gemini, targeting various health conditions.
Price reaction · baseline $1.22 (2026-03-23 close) · hit pre-market · clean, no other REVB news in the window
day 0 close · peak
-8.2%
day 1
-3.3%
day 3
-7.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • Revelation Biosciences is actively participating in a prominent conference.
  • The company is focused on innovative treatments for serious health conditions.
  • The fireside chat will be accessible to a wider audience through a live webcast.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+38%
120-day peak, hindsight
Typical move
10.5%
average across 2 past catalysts
Cash runway
~12 mo
Medium dilution risk
Lead asset
Gemini
Phase 1 · Renal Insufficiency, Chronic

Full Press Release Details

SAN DIEGO – March 24, 2026 – Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company focused on rebalancing inflammation to optimize health, today announced a reminder of its participation in a fireside chat on Tuesday, March 24, 2026, at 2:00 p.m. PT , as part of the 38th Annual Roth Conference, in Dana Point, CA.
The fireside chat will be webcast live here and available on our Investors section of the Revelation Biosciences website, www.RevBiosciences.com , after the meeting.
About Revelation Biosciences, Inc.
Revelation Biosciences, Inc. is a clinical-stage life sciences company focused on rebalancing inflammation using its proprietary formulation, Gemini. Revelation has multiple ongoing programs to evaluate Gemini as a treatment for acute kidney injury, a treatment of chronic kidney disease, prevention of post-surgical infection, and a treatment to reduce hyperinflammation and infection associated with severe burn.
For more information, please visit www.RevBiosciences.com .
Company Contacts
Mike Porter
Investor Relations
Porter LeVay & Rose Inc.
Email: mike@plrinvest.com
Chester Zygmont, III
Chief Financial Officer
Revelation Biosciences Inc.

Frequently Asked Questions

When is the fireside chat hosted by Revelation Biosciences?

The fireside chat is scheduled for March 24, 2026, at 2:00 p.m. PT.

Where will the fireside chat be held?

The chat will take place at the 38th Annual Roth Conference in Dana Point, CA.

How can I watch the fireside chat?

The fireside chat will be webcast live and available on the company's website afterward.

What is the focus of Revelation Biosciences?

The company focuses on rebalancing inflammation to optimize health with its formulation, Gemini.

ShareAdd on Google
Tags: REVB Revelation Biosciences Roth Conference Gemini clinical-stage
Last updated: Mar 24, 2026

Biotech snapshot

Cash runway
$11M liquidity · $1M/mo burn
~12 mo
Medium dilution risk
Lead asset
GeminiPhase 1
Renal Insufficiency, Chronic →

Catalyst track record

+38%
best trade around REVB's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for REVB.

See every catalyst's timing & PoA →